Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International
Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...
IPO
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO)...
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...
PegBio Files for IPO on Hong Kong Stock Exchange
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant...
Sihuan Pharmaceutical Plans IPO for Xuanzhu Biopharm on Hong Kong Stock Exchange
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced a renewed attempt to spin...
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...
Mirxes Holding Company Updates IPO Prospectus with 2024 Financials
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit...
Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...
Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation
On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co.,...
Zephyrm Bioscience Limited Files for IPO on Hong Kong Stock Exchange
China-based Zephyrm Bioscience Limited, a biopharmaceutical company specializing in the development of novel pluripotent stem...
Zephyrm Bioscience Aims for HKEX Main Board with Innovative Cell Therapy Products
Zephyrm Bioscience Limited (hereinafter referred to as “Zephyrm Bio”) officially submitted its prospectus to the...
Sinopharm’s InnoStar Bio-tech Becomes First Pharma Company to IPO on STAR in 2024
SHANGHAI—Shanghai InnoStar Bio-tech Co., Ltd., a subsidiary of Sinopharm’s China State Institute of Pharmaceutical Industry...
Duality Biotherapeutics Eyes Hong Kong IPO, Bolstering ADC Pipeline and Global Clinical Trials
HONG KONG—Duality Biologics, Inc., a Chinese biotechnology company specializing in antibody drug conjugates (ADCs), is...
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD...
TYK Medicines Inc. Targets HKD 506.3 Million in Hong Kong IPO for Drug Pipeline Expansion
TYK Medicines Inc., a pharmaceutical company headquartered in Zhejiang, is gearing up for an initial...
Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...